Galapagos reported EUR-158708000 in EBITDA for its fiscal quarter ending in March of 2025.


Ebitda Change Date
argenx SE 288.02M 84.53M Jun/2025
AstraZeneca USD 4.96B 127M Jun/2025
Biogen USD 1.01B 456.5M Jun/2025
Genmab DKK 376M 172M Jun/2025
Gilead Sciences USD 3.4B 797M Jun/2025
GlaxoSmithKline GBP 3.18B 45M Jun/2025
GRIFOLS EUR 347.24M 58.35M Jun/2025
Hikma Pharmaceutical USD 369M 84M Dec/2024
Incyte USD 581.52M 358.87M Jun/2025
Merck EUR 1.46B 45M Jun/2025
Neurocrine Biosciences USD 152.9M 121.6M Jun/2025
Novartis USD 6.17B 339M Jun/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 1.89B 971M Jun/2025
UCB EUR 1.37B 715M Dec/2024
Vertex Pharmaceuticals USD 1.34B 556.6M Jun/2025